Alexion Pharmaceuticals Inc

Most Recent

  • Alexion Acquisition AstraZeneca
    Healthcare

    AstraZeneca to Acquire Alexion for $39 Billion, Stock Down

    On Dec. 12, AstraZeneca agreed to acquire Alexion for $39 billion. The deal would bolster AstraZeneca’s footprint in rare diseases.
    By Ambrish Shah
  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Stock Performance

    After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

    By Kenneth Smith
  • uploads///GEVA ALXN LAL D
    Miscellaneous

    Backing Out of the Synageva BioPharma Deal, Part 3

    Things like acts of war and natural disasters aren’t MACS unless they disproportionately affect Synageva relative to other early-clinical-stage biopharmaceutical companies.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio

    Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

    By Margaret Patrick
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///WILSON DISEASE
    Healthcare

    Wilson Disease: A Market Opportunity for Alexion

    Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///strensiq
    Earnings Report

    Inside Alexion’s Metabolic Drugs Kanuma and Strensiq

    In 1Q16, Strensiq added $33.2 million to Alexion Pharmaceuticals’ top line. Now the drug is in its initial launch phase in the US, Germany, and Japan.

    By Jillian Dabney
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Alexion Continues to Rise on FDA’s Approval of Kanuma

    Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.

    By Peter Neil
  • uploads///CURRENT TREATMENT LIMITATIONS
    Healthcare

    WTX101: A Superior Treatment for Wilson Disease

    WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.

    By Sarah Collins
  • uploads///krystexxa
    Company & Industry Overviews

    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug

    Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.

    By Jillian Dabney
  • uploads///revue ee
    Earnings Report

    BioMarin’s Disappointing 3Q16 Earnings

    BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.

    By Jillian Dabney
  • uploads///Kanuma
    Earnings Report

    How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings

    Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.

    By Jillian Dabney
  • uploads///Graph Autosomal recessive pattern
    Company & Industry Overviews

    BioMarin Leads in the Market for Mucopolysaccharidoses Disorders

    BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.

    By Jillian Dabney
  • uploads///Strensiq
    Earnings Report

    How Alexion Plans to Fuel Strensiq Sales

    With the Enobia acquisition in February 2012, Alexion benefited in long-term disease awareness, diagnostic planning, and initiatives in the HPP space.

    By Jillian Dabney
  • uploads///ANR
    Company & Industry Overviews

    Why Are Most Analysts Recommending a ‘Buy’ for Vertex?

    On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.

    By Jillian Dabney
  • uploads///PE multiple
    Company & Industry Overviews

    Why Is Vertex Pharmaceuticals’ Valuation at a Discount?

    On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).

    By Jillian Dabney
  • uploads///AdobeStock_
    Fund Managers

    Bridgewater: What Are Ray Dalio’s Top Investing Ideas?

    Founded by Ray Dalio, Bridgewater Associates’ top sell in the third quarter was the iShares MSCI Emerging Markets ETF (EEM).

    By Rabindra Samanta
  • uploads///Biomarin
    Company & Industry Overviews

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

    By Daniel Collins
  • uploads///ALXN
    Company & Industry Overviews

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///ALXN
    Company & Industry Overviews

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    Analyzing Sarepta’s Product Pipeline

    Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

    By Kenneth Smith
  • uploads///capsule _
    Company & Industry Overviews

    How Alexion Pharmaceuticals Is Positioned in October

    In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.

    By Mike Benson
  • uploads///addiction _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.

    By Daniel Collins
  • uploads///ALNY
    Earnings Report

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Analysts Are Bullish on Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

    By Mike Benson
  • uploads///addiction _
    Earnings Report

    How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?

    BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.

    By Daniel Collins
  • uploads///FD
    Company & Industry Overviews

    Alexion Pharmaceuticals in 4Q17 and Fiscal 2017

    In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///rare diseases
    Company & Industry Overviews

    Inside Pfizer’s Rare Disease Segment Performance in 2017

    In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Spinraza
    Company & Industry Overviews

    How Biogen’s Spinraza Is Positioned for 2018

    In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis Pharmaceuticals’ January 2018 Valuation

    On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How’s Incyte’s Valuation in January 2018?

    Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

    By Mike Benson
  • uploads///digital science capabilities
    Company & Industry Overviews

    Thermo Fisher Scientific’s Deepening Ties with Sema4

    Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals

    On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Patisiran Expected to Become Key Growth Driver for Alnylam

    Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.

    By Margaret Patrick
  • uploads///Defitelio
    Company & Industry Overviews

    How Is Jazz’s Defitelio Positioned after 2Q17?

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.

    By Daniel Collins
  • uploads///Clinical trial
    Company & Industry Overviews

    This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver

    In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Behind Bioverativ’s Analyst Recommendations This September

    Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

    By Daniel Collins
  • uploads///Orkambi Kalydeco
    Company & Industry Overviews

    How Are Orkambi and Kalydeco Positioned after 2Q17?

    In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017

    Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Healthy Profit Margins in 2017

    Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Robust Revenue Growth in 2017

    In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ–True North Therapeutics: Stronger Research Pipeline

    The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand

    Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.

    By Margaret Patrick
  • uploads///Analysts Recommendations
    Company & Industry Overviews

    What Analysts Recommend for BioMarin Pharmaceuticals

    A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”

    By Daniel Collins
  • uploads///Naglazyme Aldurazyme revenues
    Company & Industry Overviews

    BioMarin Expects These Drugs to Generate Steady Revenues

    In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How Incyte’s Valuation Has Changed since 1Q17 Results

    Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

    By Mike Benson
  • uploads///Strensiq Revenues
    Company & Industry Overviews

    Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017

    In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue

    Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17

    To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant’s Net Profit Margins Expected to Narrow in 2017

    Net profit margins Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, the company will also have to bear $1.9 billion in cash interest in 2017, which includes $100 million in amortized deferred financing costs. Wall Street analysts have projected that […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis

    The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Has Adopted Multiple Approaches to Treat Cystic Fibrosis

    Vertex Pharmaceuticals (VRTX) is aiming to increase the number of patients eligible to be treated with its drugs to include the entire CF patient population.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why United Therapeutics Expects Strong Revenue Growth

    United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.

    By Margaret Patrick
  • uploads///anr
    Company & Industry Overviews

    What Are Analysts Saying about Horizon Pharma?

    According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”

    By Jillian Dabney
  • uploads///Actimmune trials
    Company & Industry Overviews

    Horizon Pharma’s Steep Fall in December: What Happened?

    On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.

    By Jillian Dabney
  • uploads///acq flexibility
    Company & Industry Overviews

    How Could Gilead Sciences Restore Its Growth?

    With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.

    By Jillian Dabney
  • uploads///orkambis success
    Earnings Report

    Why Europe Is an Important Market for Vertex’s Orkambi

    Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.

    By Jillian Dabney
  • uploads///Orkambi
    Company & Industry Overviews

    Higher Discontinuations Are among Orkambi’s Concerns

    Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.

    By Jillian Dabney
  • uploads///sovaldi patients
    Company & Industry Overviews

    How Gilead Dominates the HCV Space

    In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Will Teva Pharmaceutical Strengthen Specialty Pipeline in 3Q16?

    Teva Pharmaceutical (TEVA) has been actively involved in multiple research programs in its specialty pipeline, including MS, movement disorders, and neurodegeneration, pain, and respiratory.

    By Margaret Patrick
  • uploads///soliris opportunity
    Earnings Report

    How Significant Is Alexion’s Opportunity with Soliris?

    Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.

    By Jillian Dabney
  • uploads///guidance
    Earnings Report

    Behind Alexion’s Updated Guidance for Its Metabolic Franchise

    During the second quarter of 2016, Alexion (ALXN) witnessed 23% volume growth, resulting in an 18% annual revenue growth.

    By Jillian Dabney
  • uploads///revue ee
    Earnings Report

    Alexion’s 2Q16 Earnings Just Might Impress You

    Alexion Pharmaceuticals released its earnings for 2Q16 on July 28, reporting revenues of $753.1 million, which surpassed Wall Street analyst estimates.

    By Jillian Dabney
  • uploads///ANR
    Company & Industry Overviews

    The Word on the Street: How Analysts See BioMarin Now

    According to Bloomberg, among 20 analysts, 90% recommend BioMarin as a “buy,” and the remaining 10% of analysts have issued a “hold” rating for the company.

    By Jillian Dabney
  • uploads///Share price
    Company & Industry Overviews

    Why Did Alexion Fall after Brexit?

    Following Brexit, global equity markets experienced a crash. Anticipations of weaker European and British economies are likely reasons for the fall.

    By Jillian Dabney
  • uploads///Brexit
    Miscellaneous

    Effects of Brexit on Pharmaceuticals and the Biotechnology Industry

    Global big pharmaceutical companies that have major exposure to Europe will be impacted significantly by Brexit. The depreciating euro will impact sales.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%

    As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).

    By Peter Neil
  • uploads///angioedema
    Company & Industry Overviews

    How Does Shire Lead the Angioedema Space?

    Cinryze and Firazyr are Shire’s (SHPG) two drugs in its hereditary angioedema portfolio. Together, these two drugs crossed $1 billion in sales in fiscal 2015.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Why Has Teva Pharmaceutical Targeted Orphan Diseases?

    Similar to Alexion’s Soliris, Amgen’s blinatumomab, and Celgene’s GED-301, SD-809 has received an ODD (orphan drug designation) from the FDA.

    By Margaret Patrick
  • uploads///ADHD portfolio
    Company & Industry Overviews

    How Vyvanse Could Fuel Shire’s ADHD Portfolio Sales

    Vyvanse is Shire’s leading ADHD drug, constituting 80% of the company’s ADHD portfolio. In fiscal 2015, Vyvanse earned the company $1.7 billion.

    By Jillian Dabney
  • uploads///ANR
    Company & Industry Overviews

    Analysts Are Optimistic About Shire

    According to a Bloomberg consensus of 15 brokerage firms, 86.7% of analysts rated Shire a “buy,” and 13.3% rated it a “hold.” None issued a “sell” rating for the stock.

    By Jillian Dabney
  • uploads///PE
    Company & Industry Overviews

    Shire at Discount on Price-to-Earnings Basis: A Good Opportunity?

    With estimated double-digit sales growth and post-Baxalta-acquisition synergies, Shire’s PE could rise in the near term and result in a rise in share price.

    By Jillian Dabney
  • uploads///Natpara
    Company & Industry Overviews

    Shire’s Acquisition Gives It Natpara and Gattex

    Gattex is the first and only analog of glucagon-like peptide-2 (or GLP-2) indicated for short bowel syndrome. The drug is known as Gattex in the United States and Revestive in Europe.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Which Large-Cap Biotech Stock Fell the Most Last Week?

    Large-cap biotech stocks struggled during the week ending March 18, 2016. The large-cap stocks within the iShares Nasdaq Biotechnology ETF (IBB) suffered the most, falling 3.9% during the week.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Alexion Pushes Down IBB’s Performance

    Alexion Pharmaceuticals (ALXN) was the biggest loser among IBB’s large-cap stocks.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Biotech Stocks Begin March on a Positive Note: XLV Gained 2.1%

    On March 1, crude oil inched toward $35 per barrel. The biotech stocks also moved up along with the markets.

    By Peter Neil
  • uploads///total revenue
    Company & Industry Overviews

    What’s Vertex’s Strategy to Sustain the Cystic Fibrosis Market?

    Vertex Pharmaceuticals (VRTX) plans to continue to create high-value drugs for CF (cystic fibrosis). In 2015, CF product revenue stood at $983 million, a 110% increase in revenue.

    By Jillian Dabney
  • uploads///Anual drug projections
    Earnings Report

    Vertex Will Focus on Cystic Fibrosis Market in 2016

    In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for cystic fibrosis. In November 2015, it received approval from the European Commission to treat CF.

    By Jillian Dabney
  • uploads///Kalydeco projections
    Earnings Report

    Vertex’s Cystic Fibrosis Drugs and Their Controversial Prices

    Vertex Pharmaceuticals priced Kalydeco at $294,000 per year and recently increased the price to $311,000. Vertex is not the only company pricing its drugs at the higher end.

    By Jillian Dabney
  • uploads///Pipeline
    Earnings Report

    Will Vertex Pharmaceuticals’ Valuation Multiple Improve?

    These valuation multiples are susceptible to company- or industry-related material news. So any positive news results in a jump in the valuation multiple.

    By Jillian Dabney
  • uploads///Orkambi revenue projections
    Earnings Report

    Orkambi: Recent Addition to the Vertex Portfolio

    In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.

    By Jillian Dabney
  • uploads///Graph Kuvan
    Company & Industry Overviews

    What Are BioMarin’s Products for Treating Phenylketonuria?

    Kuvan, with the active ingredient sapropterin dihydrochloride, is effective in reducing blood phenylalanine levels in PKU (or phenylketonuria) patients.

    By Jillian Dabney
  • uploads///Graph firdapse
    Company & Industry Overviews

    BioMarin’s Firdapse for Lambert-Eaton Myasthenic Syndrome

    Firdapse is indicated for Lambert-Eaton Myasthenic syndrome. The chemical name of Firdapse is amifampridine phosphate and its active ingredient is 3,4-DAP.

    By Jillian Dabney
  • uploads///Vertex financial projections
    Earnings Report

    What Are Wall Street’s Estimates for Vertex Pharmaceuticals?

    According to Wall Street analysts’ estimates, sales for Vertex Pharmaceuticals should be $408.8 million and $472.4 million for 4Q15 and 1Q16, respectively.

    By Jillian Dabney
  • uploads///Graph naglazyme
    Company & Industry Overviews

    Naglazyme: One of the Costliest Drugs in the United States

    The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.

    By Jillian Dabney
  • uploads///Graph
    Miscellaneous

    FDA Committee Raises Concerns about Kyndrisa’s Efficacy, Safety

    On November 24, 2015, the Peripheral and Central Nervous System Drugs Advisory Committee of the FDA discussed clinical data submitted by BioMarin to support Kyndrisa’s (drisapersen) NDA.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    FDA Sets December 27, 2015, as Kyndrisa’s PDUFA Date

    The FDA has set December 27, 2015, as the PDUFA date for BioMarin Pharmaceutical’s (BMRN) Kyndrisa (drisapersen) for Duchenne Muscular Dystrophy (or DMD) Amenable to Exon 51 Skipping.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Kanuma: An Innovative Enzyme Replacement Therapy for LAL-D

    Alexion Pharmaceuticals’ Kanuma is an innovative enzyme replacement therapy for patients suffering with lysosomal acid lipase deficiency (or LAL-D).

    By Margaret Patrick
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    AbbVie Topped XBI’s Large-Cap Space

    AbbVie (ABBV) rose 6.5% on November 2, 2015. The stock has continued its strong run and has now gained for seven consecutive trading sessions.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Alexion Drove IBB’s Top Ten Performance

    Alexion Pharmaceuticals (ALXN) rose by 5.5% and closed at $161.07. ALXN broke its four-day losing streak and moved into the green.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Key Risks that Alexion Pharmaceuticals Faces

    Alexion Pharmaceuticals (ALXN) depends on a single drug Soliris for most of its revenues, which is a key risk for the company.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Acquires Synageva BioPharma

    In June 2015, Alexion (ALXN) acquired Synageva BioPharma for $8.4 billion, creating a robust pipeline in the biotechnology industry.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Key Risks Vertex Pharmaceuticals Faces

    Biotechnology companies such as Regeneron, Alexion, Vertex, and Biogen have excessive business concentration risk, since they earn the majority of their revenues from a small number of drugs.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals’ Cost Structure and EBITDA Margins

    Mature biotechnology companies generally earn EBITDA margins of about 30% to 40%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Illumina: Investor’s Overview of a Leading Biotechnology Company

    An overview of Illumina, a leading biotechnology company, which holds a market capitalization of $27.5 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Cost Structure and EBITDA Margins

    While mature biotechnology companies with drugs in multiple disease segments earn an average of 30%–40% EBITDA, margins of companies targeting only rare diseases can vary due to unique business models.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Diversifies Its Research Pipeline

    Alexion Pharmaceuticals (ALXN) has strengthened its drug pipeline by diversifying its research programs across the metabolic disorder segment.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.